Table 4.
Comparison of safety and effectiveness with large bore aspiration catheters
| Reference | Patients/device | mTICI 2B-3 (final/only aspiration) |
Safety (sICH/ENT) | mRS 0–2 90 days | Mortality |
| Mohlenbruch (2019)10 | 85/SOFIA PLUS (Microvention) |
96.5%/64.7% | 4.7%/4.7% | 49.4% | 20% |
| De Marini (2019)11 | 41/ARC (Medtronic) |
98%/85% | 2%/2.5% | 49% | 10% |
| Bretzner (2019)12 | 60/AXS Catalyst (Stryker) |
86.7%/83.3% | 5%/NR | 48.3% | 21.7% |
| Marnat (2019)13 | 296/SOFIA 5–6F (Microvention) |
86.1%/NR | 6.2%/NR | 43% | 22.9% |
| Schramm (2019)15 | 204/ACE64/68 (Penumbra) |
93.1%/70.6% | 2.9%/1.5% | 61% | 7.5% |
| Raymond (2020)16 | 47/REACT 68 (Medtronic) |
95.7%/53.2% | 4.3%/NR | 23.5% | NR |
| Bilgin (2021)14 | 148/SOFIA 6F (Microventrion) |
89.1%/69.2% | 5.4%/5.4% | 49.3% | 14.1% |
| TAPAS | 45/MIVI Q | 93.3 %/73.3% | 2.2%/0% | 55.6% | 13.3% |
ENT, embolism new territory; NR, not reported; sICH, symptomatic intracranial hemorrhage.